Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

AnPac Bio-Medical Science Co., Ltd. (ANPC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.2737-0.0143 (-4.97%)
At close: 04:00PM EDT
0.2716 -0.00 (-0.77%)
After hours: 07:18PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.2880
Open0.2800
Bid0.2725 x 1100
Ask0.2798 x 900
Day's Range0.2720 - 0.2878
52 Week Range0.2030 - 4.5200
Volume488,673
Avg. Volume1,103,331
Market Cap6.903M
Beta (5Y Monthly)1.57
PE Ratio (TTM)N/A
EPS (TTM)-1.0390
Earnings DateJul 04, 2022 - Jul 10, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ANPC

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • AnPac Bio-Medical Science Co.,
    Daily – Vickers Top Buyers & Sellers for 04/19/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • GlobeNewswire

    AnPac Bio Regains Compliance with Requirements to Remain Listed on Nasdaq Capital Market

    PHILADELPHIA, June 10, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that The Nasdaq Stock Market LLC (“Nasdaq”) notified the Company on June 9, 2022 that Nasdaq has determined the Company has regained compliance with the requirements to remain listed in The Nasdaq Capital Market, as required by a hearing pan

  • GlobeNewswire

    AnPac Bio Reports 49.1% Decrease in Net Loss in First Quarter of Fiscal 2022

    PHILADELPHIA, May 31, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today its unaudited financial results for the first quarter ended March 31, 2022. The Company’s financial statements and related financial information for the quarter ended March 31, 2022 are unaudited and have not been reviewed by the Company’s independent registered accountant. T

  • GlobeNewswire

    AnPac Bio Reports Fiscal Year 2021 Annual Financial Results

    PHILADELPHIA, May 16, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today its annual financial results for the year ended December 31, 2021. Financial Highlights for Fiscal Year 2021 Total revenues were RMB18.0 million (US$2.8 million) in fiscal year 2021, a decrease of 12.3% from RMB20.5 million (US$3.1 million) in fiscal year 2020.Gross margin wa

Advertisement
Advertisement